Heart to heart with trastuzumab: A review on cardiac toxicity

Targeted Oncology

Volumn 6, Issue 4, 2011, Pages 189-195

  Di Cosimo, Serena ^a,b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Breast cancer; Cardiotoxicity; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE SEQUENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; SYSTOLIC DYSFUNCTION; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HEART DISEASES; HUMANS;

EID: 84856049297     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0203-8     Document Type: Review

References (33)

1. Slamon DJ (1987) Proto-oncogenes and human cancers. N Engl J Med 317(15):955-957 (Pubitemid 17147940)
2. Carter P et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89(10):4285-4289
3. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792 (Pubitemid 32222155)
4. Marty M et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265-4274 (Pubitemid 46207001)
5. Baselga J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):737-744
6. Vogel CL et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719-726 (Pubitemid 34111379)
7. Dahabreh IJ et al (2008) Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6):620-630 (Pubitemid 351904907)
8. Gianni L et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377-384
9. Russell SD et al (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28(21):3416-3421
10. Smith LA et al (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337
11. Floyd JD et al (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23(30):7685-7696 (Pubitemid 46291833)
12. Viani GA et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153
13. Ozcelik C et al (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99(13):8880-8885 (Pubitemid 34693652)
14. Crone SA et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459-465 (Pubitemid 34546747)
15. Lemmens K, Doggen K, De Keulenaer GW (2007) Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116 (8):954-960 (Pubitemid 47300920)
16. Liu X et al (2006) Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48(7):1438-1447 (Pubitemid 44436803)
17. Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (16):1673-1684 (Pubitemid 41464706)
18. Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659-1672 (Pubitemid 41464705)
19. Baselga J et al (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13):2825-2831 (Pubitemid 28311914)
20. Jarvinen TA, Liu ET (2000) Effects of HER-2/neu on chemosensitivity of tumor cells. Drug Resist Updat 3(6):319-324 (Pubitemid 32118397)
21. Bianchi G et al (2003) Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9(16 Pt 1):5944-5951 (Pubitemid 38018080)
22. Untch M et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28(12):2024-2031
23. Harris L et al (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1):25-36 (Pubitemid 34049039)
24. Batist G et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19(5):1444-1454 (Pubitemid 32202552)
25. Cortes J et al (2009) Nonpegylated liposomal doxorubicin (TLCD99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 15(1):307-314
26. Chia S et al (2006) Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24(18):2773-2778 (Pubitemid 46630575)
27. de la Fouchardiere C et al (2009) Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE. Ann Oncol 20(12):1959-1963
28. Martin M et al (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol
29. Joensuu H et al (2011) Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol
30. Fallah-Rad N, Walker JR, Wassef A et al (2011) J Am Coll Cardiol 57:2263-2270
31. Guarneri V et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24(25):4107-4115 (Pubitemid 46622286)
32. Swedberg K et al (2008) Successful treatment of heart failure with devices requires collaboration. Eur J Heart Fail 10(12):1229-1235
33. Seidman A et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215-1221 (Pubitemid 34177427)